Blume-Jensen Peter sold ACRV
August 18, 2026 · Form 4 insider transaction
Blume-Jensen Peter sold 1,229 shares of Acrivon Therapeutics, Inc. at $2.01 per share, a transaction worth $2.5K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Disposed (sell-side)
Shares
1,229
Price
$2.01
Total value
$2.5K
InsiderBlume-Jensen Peter
RoleOfficer, Director
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateAugust 18, 2026
Filing dateAugust 20, 2026
Shares owned after2,244,088
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.; These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.